Skip to content
Asacol

Asacol

Active ingredient: Mesalazine

Package

AED 489.54

AED 696.50 AED 734.31 Save 5%

Free delivery on orders from AED 796.00, free express delivery from AED 1,194.00

Delivery: from 4 days

Ulcerative colitis and related inflammatory bowel conditions can cause diarrhoea, rectal bleeding and abdominal pain. Asacol contains mesalazine, also called mesalamine, an anti-inflammatory ingredient designed to act in the bowel. It may help settle active inflammation and support remission when prescribed for the individual pattern and severity of disease.

Product information

Asacol is an oral mesalazine anti-inflammatory used mainly in treatment plans for ulcerative colitis. The medicine belongs to the aminosalicylate group of anti-inflammatory treatments used in inflammatory bowel disease.

How it affects the body

The active ingredient then acts mainly on the bowel lining, where it reduces inflammatory signalling and helps limit local tissue irritation. The mechanism is local rather than a broad suppression of the entire immune system.

Ingredients

Asacol contains mesalazine. Mesalamine is the alternative international name for the same active ingredient. The medicine belongs to the aminosalicylate group of anti-inflammatory treatments used in inflammatory bowel disease.

Its modified-release formulation is designed to release mesalazine in the gastrointestinal tract rather than immediately after swallowing. The active ingredient then acts mainly on the bowel lining, where it reduces inflammatory signalling and helps limit local tissue irritation. The mechanism is local rather than a broad suppression of the entire immune system.

Mesalazine and Mesalamine Naming

Mesalazine and mesalamine describe the same active pharmaceutical ingredient. The names differ according to regional naming conventions. Formulation and strength still matter because different products may release the ingredient in different parts of the digestive tract.

Modified-Release Delivery

Modified-release tablets must be handled as directed for that specific formulation. Crushing, chewing or splitting can interfere with the intended release profile unless a prescriber or pharmacist has confirmed that the action is suitable for the product.

Swallowing difficulty should be dealt with before treatment begins. Do not alter a modified-release tablet simply because it seems large; ask for a formulation-specific solution.

Dosage and administration

  • Use the prescribed dose and schedule.
  • Take each dose at the instructed time.
  • Swallow the modified-release pill as directed.
  • Keep the routine consistent during symptom improvement and remission.
  • Do not increase, reduce or stop treatment without a treatment decision from the prescriber.
  • The regimen for the chosen strength is confirmed with a healthcare professional before starting.

The required regimen differs between active disease and maintenance treatment. A person may need a different plan during a flare than during remission. Taking extra pills when symptoms worsen can create risk without addressing the reason for deterioration.

Administration Routine

A fixed daily routine can make missed doses less likely. Linking the dose with a regular activity, such as breakfast or an evening meal, may help, provided the prescribed instructions allow that timing. If a dose is missed, follow the specific missed-dose direction for the product and avoid taking two doses together unless expressly instructed.

Adherence During Remission

Some patients stop treatment after bleeding and diarrhoea improve. That can remove the maintenance effect before the underlying inflammatory tendency is stable. Long-term treatment is not identical for every person, so continuation should follow the individual plan rather than an internet schedule.

Keep a simple record of bowel symptoms, bleeding and missed doses. This gives the prescriber more useful information than relying on memory during a short appointment.

When not to use it

Asacol is not suitable for a person with a previous serious reaction to mesalazine, mesalamine, salicylates or a relevant excipient. The prescriber also needs to know about kidney disease, liver disease, stomach or duodenal ulcers, blood disorders and previous intolerance to bowel anti-inflammatory medicines.

When this is not for you

Asacol may not be for you if you have had a serious reaction to mesalazine, salicylates or an excipient, or if a clinician considers another treatment more suitable.

Pregnancy and breastfeeding require an individual discussion that considers disease activity, treatment benefits and alternatives. Active inflammatory bowel disease can itself create risks, so treatment decisions should not be made by stopping medicine abruptly.

Possible side effects

Mesalazine is often tolerated, but digestive symptoms, headache, nausea and skin reactions can occur. Some of these symptoms overlap with ulcerative colitis itself, so a new or persistent problem may need clinical assessment rather than being dismissed as a normal flare.

Possible effects Urgent warning signs
Nausea, headache or abdominal discomfort Facial swelling, breathing difficulty or collapse
Diarrhoea or worsening bowel discomfort Severe rash, severe chest pain or marked weakness
Skin irritation or mild rash Reduced urine, blood in urine or new flank pain

Commonly Reported Effects

Nausea, headache, abdominal pain, indigestion and changes in bowel movements are reported with mesalazine products. A mild symptom that settles may be monitored within the agreed treatment plan, while persistent diarrhoea, repeated vomiting or worsening pain needs medical review.

A practical difficulty is that an adverse effect and an inflammatory bowel flare can look similar; the timing of symptoms, associated fever or rash, urine changes and blood-test findings can help a clinician distinguish between them.

Serious Reactions and Emergency Symptoms

Seek emergency help for breathing difficulty, facial or throat swelling, collapse, severe chest pain or a rapidly spreading blistering rash. Prompt medical assessment is also needed for reduced urine, blood in the urine, new flank pain, unusual bruising, severe sore throat or a sudden major worsening of diarrhoea.

New flank pain or a marked reduction in urine should not be treated as an ordinary ulcerative colitis symptom. Mesalazine can rarely affect kidney function, so these signs require prompt assessment.

Therapeutic indications

Asacol is an oral mesalazine anti-inflammatory used mainly in treatment plans for ulcerative colitis. A clinician may prescribe it during an active flare, after symptoms improve to help maintain remission, or as part of a longer treatment plan intended to reduce relapses. Its suitability depends on the extent of bowel inflammation, disease severity, previous response and the formulation prescribed.

Mesalazine treats inflammatory activity in the bowel lining. It does not simply mask pain or diarrhoea, and symptom improvement does not always mean that inflammation has completely settled. Persistent rectal bleeding, ongoing diarrhoea, fever, weight loss or increasing abdominal pain needs medical review because these symptoms may indicate active disease or a complication.

Clinical Uses of Mesalazine

Ulcerative colitis is the main condition associated with Asacol. Mesalazine may be used when inflammation affects the rectum, left side of the colon or a wider area, although the suitable formulation and route depend on where the disease is active. Guidelines from NICE and the American College of Gastroenterology (ACG) describe aminosalicylates as an important treatment category for ulcerative colitis, with treatment adjusted according to response and disease extent [1].

Treatment Goals and Expected Benefits

Treatment goals include reducing bleeding and stool frequency, settling bowel inflammation and maintaining a stable period without significant symptoms. Improvement can take time, and a clinician may review symptoms, blood tests, stool markers or endoscopic findings before changing the plan. Potential benefits include reduced bleeding, fewer bowel symptoms and support for remission; possible drawbacks include adverse effects, monitoring needs and the possibility that the chosen formulation will not control active disease.

Comparison

Asacol belongs to the mesalazine anti-inflammatory category. Treatment selection depends on the distribution of inflammation, severity, prior response, kidney function and the monitoring required.

Treatment category Typical clinical role Main limitation
Oral mesalazine Bowel inflammation across a wider area Formulation may not suit every disease location
Topical mesalazine Inflammation close to the rectum or left colon Administration route may be inconvenient
Corticosteroid, immune-modifying or biologic treatment More active, extensive or resistant disease Greater monitoring and treatment-specific risks

Other mesalazine formulations may contain the same active ingredient but release it in different parts of the bowel. Tablet counts should never be converted between presentations without medical instruction. Corticosteroids may be used for selected flares, while immune-modifying or biologic therapies may be considered when inflammation is extensive or does not respond adequately to aminosalicylates.

The EMA describes mesalazine products as locally acting anti-inflammatory medicines, while treatment guidelines place them within a wider stepwise approach to ulcerative colitis care [2].

Common mistakes

  • Stopping Asacol as soon as bleeding settles.
  • Crushing, chewing or splitting a modified-release pill.
  • Doubling the next dose after a missed dose.
  • Assuming every bout of diarrhoea is a treatment side effect.
  • Ignoring reduced urine or new flank pain.
  • Starting frequent non-steroidal anti-inflammatory pain relief without review.
  • Failing to mention kidney disease, salicylate intolerance or anticoagulant treatment.
  • Changing from one mesalazine presentation to another by counting pills.
Symptom improvement does not authorise a dose reduction. The maintenance plan is separate from the short-term response to a flare.

One frequent misconception is that all mesalazine products can be swapped unit for unit. Release location and strength can differ, so a tablet from one presentation may not equal a tablet from another.

What doctors say

In clinical practice, doctors often separate three questions: are symptoms improving, is inflammation reducing, and is the treatment tolerable enough to continue? Asacol can support bowel control, yet a person with persistent bleeding or worsening pain may need reassessment rather than a self-directed dose increase.

A gastroenterology team may use symptoms alongside blood tests, stool inflammatory markers or endoscopy. The WHO’s essential-medicines framework recognises the importance of rational, condition-specific medicine use, including attention to adverse effects and monitoring [3].

Doctors also focus on adherence during remission. Missing occasional doses may seem harmless, but repeated omissions can make it difficult to judge whether the treatment itself is working. A clear record of doses, bowel movements and warning symptoms helps the clinical team make a more accurate decision.

Common questions

Is Asacol suitable for older adults?

Older adults may use mesalazine when the prescriber considers it appropriate, but kidney function and concurrent medicines deserve close attention. Age-related reduction in renal function can increase vulnerability to adverse effects, so FDA product information (2013) for mesalamine emphasises patient-specific assessment and monitoring; this remains relevant in 2026 [4].

A person aged 69 or older should report reduced urine, dehydration, unusual bruising or new flank pain promptly. Anticoagulants, diuretics and medicines that affect the kidneys may alter the monitoring plan. The prescribed regimen for the chosen Asacol presentation should be confirmed before treatment starts.

How long does an Asacol course last, and is long-term use acceptable?

The duration depends on whether Asacol is being used to settle active ulcerative colitis or maintain remission. Some patients require continuing treatment, while others need a different plan after clinical reassessment. NICE (2019) guidance supports treatment decisions based on response, disease activity and the balance between benefits and adverse effects.

Long-term use can be appropriate when monitoring remains satisfactory and the treatment continues to provide benefit, with kidney, liver and blood assessments forming part of follow-up. Do not stop a maintenance regimen solely because symptoms have improved.

Can Asacol be combined with anticoagulants or other medicines?

Anticoagulants, antiplatelet medicines, thiopurines, kidney-affecting medicines and regular non-steroidal anti-inflammatory drugs may require a medication review. The concern varies according to the individual’s health, dose and treatment combination. The ACG (2019) guideline supports checking the complete medicine list before starting or adding treatment [5].

Include prescribed medicines, over-the-counter pain relief and supplements, and report vomiting, dehydration or reduced urine because these conditions can increase kidney risk. A new medicine should not be added to the regimen without checking its suitability with a healthcare professional.

Which symptoms mean that Asacol should be stopped and urgent help sought?

Breathing difficulty, facial or throat swelling, collapse, severe chest pain or a rapidly spreading severe rash require emergency help, while reduced urine, blood in the urine, new flank pain or severe abdominal pain need urgent medical assessment. The EMA (2021) product information advises prompt review for sudden worsening diarrhoea with fever or marked weakness.

Do not take another dose while awaiting emergency advice if a severe allergic reaction is suspected. For less severe symptoms, contact the prescriber promptly rather than making repeated dose changes independently. The exact strength and number of pills taken should be available for the clinical assessment.

What is the best time of day to take Asacol?

The best time is the time specified for the prescribed regimen, taken consistently each day; some people link the dose with a regular meal or daily activity to reduce missed doses, but food instructions can vary by formulation. The EMA (2021) information for mesalazine products places emphasis on following the administration directions for the specific presentation.

Do not move all doses to one time or change the schedule to compensate for a missed dose. If the timing is unclear, obtain formulation-specific advice before starting. A consistent routine is useful, but it must not override the prescribed schedule.

Does Asacol cause headache?

Headache is a recognised possible adverse effect of mesalazine, although it may also result from dehydration, infection or another medicine; a mild headache that passes should still be recorded if it recurs. A severe headache with fever, neck stiffness, confusion, rash or neurological symptoms needs urgent assessment.

The WHO (2019) explains that adverse-effect assessment requires attention to timing, severity and other possible causes rather than assuming every symptom comes from one medicine. Do not stop long-term treatment for a minor symptom without advice, but seek prompt help if the headache is severe, sudden or accompanied by other warning signs.

Do you offer anonymous delivery?

Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.

Sources

  1. National Institute for Health and Care Excellence (NICE) (2019). Ulcerative colitis: management (NG130).
  2. European Medicines Agency (EMA) (2021). Summary of Product Characteristics (SmPC) — mesalazine.
  3. World Health Organization (WHO) (2019). WHO Model List of Essential Medicines, 21st List.
  4. U.S. Food and Drug Administration (FDA) (2013). Asacol HD (mesalamine) prescribing information.
  5. American College of Gastroenterology (ACG) (2019). Clinical Guideline: Ulcerative Colitis in Adults.

How Buyers Rate Asacol

4 Based on 5 reviews
Mona, 38 Sharjah Several weeks
15 Oct 2026
Rating: 2.5 out of 5
I took the prescribed dose for several weeks during a period of frequent bowel symptoms, but it did not give me the improvement I hoped for. My symptoms continued, and I stopped after discussing the side effects and lack of benefit with my doctor.
Karim R., 69 Khor Fakkan Several weeks
27 Oct 2026
Rating: 4 out of 5
I took the prescribed dose for several weeks and noticed a clear reduction in urgency after taking Asacol as prescribed. My mornings became easier to manage, and I was satisfied with the improvement.
Aisha B., 50 Umm Al Quwain Several weeks
29 Oct 2026
Rating: 3.5 out of 5
I took the prescribed dose for several weeks, and Asacol helped reduce the bleeding, although the improvement was slower than I expected. I also had some mild nausea at first, so I kept track of it and raised it during my follow-up.
Ayesha H., 59 Al Nahda Several weeks
6 Nov 2026
Rating: 5 out of 5
I took the prescribed dose for several weeks, and the treatment helped me regain a more predictable routine. I took it consistently and felt that the benefit became clearer after some time rather than immediately.
Rose, 51 Al Ain Several weeks
10 Nov 2026
Rating: 5 out of 5
I took the prescribed dose for several weeks and had a noticeable improvement in bowel frequency after following the prescribed schedule. It made daily activities less disruptive, and I was pleased with the result.
Get our free app Shop faster and track your orders 4.0 · 268 reviews Install